What are the latest guidelines for the management of gynecologic cancers, including cervical, ovarian, endometrial, vulvar, and vaginal cancers?

Latest Guidelines in Gynecologic Oncology

The most current evidence-based guidelines for gynecologic cancers have been comprehensively updated by major international societies between 2023-2024, with NCCN, ESGO, ESTRO, and ESP providing detailed management algorithms across all major gynecologic malignancies.

Cervical Cancer

Screening and Prevention

• Primary HPV testing and co-testing with cytology are now standard screening modalities, with emerging evidence supporting cervical and vaginal self-collection to improve access in underserved populations 1
• The WHO goal remains cervical cancer elimination by 2030 through enhanced vaccination and screening programs 2

Treatment of Locally Advanced Disease

• Pembrolizumab combined with chemoradiotherapy (based on KEYNOTE-018) has demonstrated unprecedented survival outcomes and received regulatory approval for locally advanced cervical cancer 2
• External beam radiation therapy (EBRT) plus brachytherapy with or without platinum-based chemosensitization remains the standard approach 3
• The 2023 ESGO/ESTRO/ESP guidelines provide comprehensive algorithms covering staging, fertility-sparing treatment, early and locally advanced disease, and cervical cancer in pregnancy 4

Recurrent and Metastatic Disease

• Bevacizumab added to chemotherapy has improved survival in advanced disease 2
• Immune checkpoint inhibitors (pembrolizumab and cemiplimab) show significant benefits in both first-line and later-line settings 2
• Antibody-drug conjugates, particularly tisotumab vedotin, have emerged as promising options with ongoing studies exploring HER2, TROP-2, mesothelin, and nectin-4 targets 2

Endometrial Cancer

Risk-Stratified Adjuvant Therapy

The NCCN 2023 guidelines provide clear risk-based algorithms 3:

Stage IA, Grade 1-2:

• Observation is preferred for most patients 3
• Vaginal brachytherapy is strongly suggested for patients ≥60 years and/or those with lymphovascular space invasion (LVSI) 3

Stage IA, Grade 3:

• Vaginal brachytherapy is preferred, especially in surgically staged patients 3
• Observation can be considered only if no myometrial invasion is present 3
• EBRT is a category 2B option if age ≥70 years or LVSI present 3

Stage IB, Grade 1-2:

• Vaginal brachytherapy is preferred 3
• Observation can be considered if no adverse risk factors present 3
• EBRT should be considered in grade 2 tumors with additional risk factors (age ≥60 years and/or LVSI) 3

Stage IB, Grade 3:

• Systemic therapy is added as category 2B option in addition to EBRT and/or vaginal brachytherapy when adverse risk factors present 3

Key Principles

• Adjuvant radiation should be initiated as soon as vaginal cuff heals, but no later than 12 weeks post-surgery 3
• The PORTEC-2 trial demonstrated low pelvic recurrence with vaginal brachytherapy alone in selected patients 3
• Adjuvant RT improves pelvic control and may improve progression-free survival, though overall survival benefit has not been consistently demonstrated 3

Cervical Involvement

• For suspected gross cervical involvement not suited for primary surgery, EBRT and brachytherapy is effective with or without platinum-based chemosensitization 3
• Systemic therapy alone is a category 2B primary treatment option, but should be followed by EBRT plus brachytherapy if patient remains inoperable 3

Fertility Preservation

• Hormonal therapy (medroxyprogesterone acetate or megestrol acetate) may be considered for fertility preservation 3
• Patients receiving hormonal therapy alone require close monitoring with endometrial biopsies every 3-6 months 3

Surgical Advances

• Ongoing trials are investigating sentinel lymph node mapping and robotic-assisted hysterectomy as alternatives to traditional staging procedures 5

Vulvar Cancer

Systemic Therapy for Advanced Disease

NTRK Fusion-Positive Tumors:

• Larotrectinib and entrectinib are FDA-approved for NTRK gene fusion-positive solid tumors after progression on standard therapy 3
• Larotrectinib demonstrated 79% objective response rate with median duration of response of 35.2 months and median PFS of 28.3 months in long-term follow-up 3
• Entrectinib showed 61% complete or partial response rate with median duration of response of 20 months 3
• NCCN now recommends larotrectinib and entrectinib as second-line or subsequent therapy (upgraded from category 2B to category 2A evidence) for NTRK gene fusion-positive vulvar tumors 3

Comprehensive Management

• The 2023 ESGO guidelines cover diagnosis, referral, staging, pathology, pre-operative investigations, surgical management (local treatment, groin treatment, sentinel lymph node procedure, reconstructive surgery), chemoradiotherapy, systemic treatment, and recurrent disease management 6
• Ongoing trials are exploring neoadjuvant chemotherapy and replacement of inguinofemoral lymphadenectomy with chemoradiation in selected patients 5

Vaginal Cancer

Multidisciplinary Approach

• The 2023 ESTRO/ESGO/SIOPe guidelines provide comprehensive coverage of diagnostic pathways, surgical, radiotherapeutic, and systemic management for both adult patients (including rare histological subtypes) and pediatric patients (vaginal rhabdomyosarcoma and germ cell tumors) 7
• Guidelines address prevention, early detection, presentation, initial investigations, referral, and diagnostic workup 8

Common Pitfalls

• Few specific timeframes are provided in available guidelines, requiring clinical judgment 8
• Consistency exists across guidelines but specificity is often lacking 8

Ovarian Cancer

Surgical Trials

• Randomized trials are currently assessing the role of lymphadenectomy in early-stage disease 5
• Studies are evaluating optimal timing of cytoreductive surgery (primary versus interval) 5
• Hyperthermic intraperitoneal chemotherapy is being investigated, even in platinum-resistant recurrence cases 5

Survivorship and Long-Term Care

Treatment-Related Toxicities

Gynecologic cancer survivors face multiple long-term complications 3:

• Surgical: Adhesions causing pain and small bowel obstruction, urinary/gastrointestinal complications (incontinence, diarrhea), pelvic floor dysfunction, lymphedema 3
• Chemotherapy: Neurotoxicity, cardiac toxicity, cognitive dysfunction, risk of hematologic cancers 3
• Hormonal therapy: Hot flashes, vaginal dryness, bone loss from estrogen deprivation 3
• Radiation: Fibrosis, stenosis, vulvovaginal atrophy, increased risk of secondary cancers in radiation field, bone loss and pelvic fracture risk 3

Survivorship Care Essentials

• All survivors should receive regular general medical care focusing on chronic disease management (depression, diabetes, hypertension), cardiovascular risk monitoring, recommended vaccinations, and healthy lifestyle promotion (exercise, smoking cessation) 3
• Comprehensive documentation of treatment history with thorough physical examination and appropriate imaging/laboratory testing is essential 3
• All patients, whether sexually active or not, should be asked about genitourinary symptoms including vulvovaginal dryness 3
• Post-radiation vaginal dilator use should be discussed 3
• Bone density testing and prophylactic bisphosphonates should be considered, particularly in patients with osteoporosis and prior pelvic radiation 3

COVID-19 Pandemic Considerations

Treatment Modifications

• Hypofractionated radiation therapy should be used when feasible to reduce patient and staff exposure 9
• Concurrent chemotherapy may be limited; radiation alone should be considered 9
• Priority scales have been established for all gynecologic malignancies with specific recommendations for dose, timing, and technique for external beam and brachytherapy 9